BIOGEN INC. Share-based Payment Arrangement, Expense, after Tax
BIOGEN INC. (BIIB) reported Share-based Payment Arrangement, Expense, after Tax of $87.80 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2026-04-29
- BIOGEN INC. share-based payment arrangement, expense, after tax for the quarter ending 2026-03-31 was $87.80M, a 4.40% increase year-over-year.
- BIOGEN INC. share-based payment arrangement, expense, after tax for the quarter ending 2025-12-31 was $62.90M, a 18.63% decline year-over-year.
- BIOGEN INC. share-based payment arrangement, expense, after tax for the quarter ending 2025-09-30 was $78.40M, a 40.20% decline year-over-year.
- BIOGEN INC. share-based payment arrangement, expense, after tax for the quarter ending 2025-06-30 was $78.10M, a 7.13% increase year-over-year.
- BIOGEN INC. share-based payment arrangement, expense, after tax for fiscal 2025 was $303.50M, a 13.95% decline from fiscal 2024.
- BIOGEN INC. share-based payment arrangement, expense, after tax for fiscal 2024 was $352.70M, a 47.23% decline from fiscal 2023.
- BIOGEN INC. share-based payment arrangement, expense, after tax for fiscal 2023 was $668.40M, a 144.30% increase from fiscal 2022.
- BIOGEN INC. share-based payment arrangement, expense, after tax for fiscal 2022 was $273.60M, a 5.72% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|---|---|---|
| 2026-03-31 | $87.80M 10-Q · filed 2026-04-29 | $150.70M derived: sum of 2 quarters · filed 2026-04-29 | $229.10M derived: sum of 3 quarters · filed 2026-04-29 | $307.20M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $62.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $141.30M derived: sum of 2 quarters · filed 2026-02-06 | $219.40M derived: sum of 3 quarters · filed 2026-02-06 | $303.50M 10-K · filed 2026-02-06 |
| 2025-09-30 | $78.40M 10-Q · filed 2025-10-30 | $156.50M derived: sum of 2 quarters · filed 2025-10-30 | $240.60M 10-Q · filed 2025-10-30 | $317.90M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $78.10M 10-Q · filed 2025-07-31 | $162.20M 10-Q · filed 2025-07-31 | $239.50M derived: sum of 3 quarters · filed 2026-04-29 | $370.60M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $84.10M 10-Q · filed 2026-04-29 | $161.40M derived: sum of 2 quarters · filed 2026-04-29 | $292.50M derived: sum of 3 quarters · filed 2026-04-29 | $365.40M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $77.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $208.40M derived: sum of 2 quarters · filed 2026-02-06 | $281.30M derived: sum of 3 quarters · filed 2026-02-06 | $352.70M 10-K · filed 2026-02-06 |
| 2024-09-30 | $131.10M 10-Q · filed 2025-10-30 | $204.00M derived: sum of 2 quarters · filed 2025-10-30 | $275.40M 10-Q · filed 2025-10-30 | $334.10M derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-06-30 | $72.90M 10-Q · filed 2025-07-31 | $144.30M 10-Q · filed 2025-07-31 | $203.00M derived: sum of 3 quarters · filed 2026-02-06 | $655.00M derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-03-31 | $71.40M 10-Q · filed 2025-05-01 | $130.10M derived: sum of 2 quarters · filed 2026-02-06 | $582.10M derived: sum of 3 quarters · filed 2026-02-06 | $658.40M derived: sum of 4 quarters · filed 2026-02-06 |
| 2023-12-31 | $58.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $510.70M derived: sum of 2 quarters · filed 2026-02-06 | $587.00M derived: sum of 3 quarters · filed 2026-02-06 | $668.40M 10-K · filed 2026-02-06 |
| 2023-09-30 | $452.00M 10-Q · filed 2024-10-30 | $528.30M derived: sum of 2 quarters · filed 2024-10-30 | $609.70M 10-Q · filed 2024-10-30 | $681.40M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $76.30M 10-Q · filed 2024-08-01 | $157.70M 10-Q · filed 2024-08-01 | $229.40M derived: sum of 3 quarters · filed 2025-02-12 | $300.40M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $81.40M 10-Q · filed 2024-04-24 | $153.10M derived: sum of 2 quarters · filed 2025-02-12 | $224.10M derived: sum of 3 quarters · filed 2025-02-12 | $283.20M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $71.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $142.70M derived: sum of 2 quarters · filed 2025-02-12 | $201.80M derived: sum of 3 quarters · filed 2025-02-12 | $273.60M 10-K · filed 2025-02-12 |
| 2022-09-30 | $71.00M 10-Q · filed 2023-11-08 | $130.10M derived: sum of 2 quarters · filed 2023-11-08 | $201.90M 10-Q · filed 2023-11-08 | $260.70M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $59.10M 10-Q · filed 2023-07-25 | $130.90M 10-Q · filed 2023-07-25 | $189.70M derived: sum of 3 quarters · filed 2024-02-14 | $251.80M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $71.80M 10-Q · filed 2023-04-25 | $130.60M derived: sum of 2 quarters · filed 2024-02-14 | $192.70M derived: sum of 3 quarters · filed 2024-02-14 | $252.10M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $58.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $120.90M derived: sum of 2 quarters · filed 2024-02-14 | $180.30M derived: sum of 3 quarters · filed 2024-02-14 | $258.80M 10-K · filed 2024-02-14 |
| 2021-09-30 | $62.10M 10-Q · filed 2022-10-25 | $121.50M derived: sum of 2 quarters · filed 2022-10-25 | $200.00M 10-Q · filed 2022-10-25 | $249.80M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $59.40M 10-Q · filed 2022-07-20 | $137.90M 10-Q · filed 2022-07-20 | $187.70M derived: sum of 3 quarters · filed 2023-02-15 | $227.30M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $78.50M 10-Q · filed 2022-05-03 | $128.30M derived: sum of 2 quarters · filed 2023-02-15 | $167.90M derived: sum of 3 quarters · filed 2023-02-15 | $213.40M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $49.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $89.40M derived: sum of 2 quarters · filed 2023-02-15 | $134.90M derived: sum of 3 quarters · filed 2023-02-15 | $211.30M 10-K · filed 2023-02-15 |
| 2020-09-30 | $39.60M 10-Q · filed 2021-10-20 | $85.10M derived: sum of 2 quarters · filed 2021-10-20 | $161.50M 10-Q · filed 2021-10-20 | $204.90M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | $45.50M 10-Q · filed 2021-07-22 | $121.90M 10-Q · filed 2021-07-22 | $165.30M derived: sum of 3 quarters · filed 2022-02-03 | $214.90M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | $76.40M 10-Q · filed 2021-04-22 | $119.80M derived: sum of 2 quarters · filed 2022-02-03 | $169.40M derived: sum of 3 quarters · filed 2022-02-03 | $252.30M derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | $43.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $93.00M derived: sum of 2 quarters · filed 2022-02-03 | $175.90M derived: sum of 3 quarters · filed 2022-02-03 | $225.40M 10-K · filed 2022-02-03 |
| 2019-09-30 | $49.60M 10-Q · filed 2020-10-21 | $132.50M derived: sum of 2 quarters · filed 2020-10-21 | $182.00M 10-Q · filed 2020-10-21 | $220.00M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | $82.90M 10-Q · filed 2020-07-22 | $132.40M 10-Q · filed 2020-07-22 | $170.40M derived: sum of 3 quarters · filed 2021-02-03 | $220.80M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $49.50M 10-Q · filed 2020-04-23 | $87.50M derived: sum of 2 quarters · filed 2021-02-03 | $137.90M derived: sum of 3 quarters · filed 2021-02-03 | $180.70M derived: sum of 4 quarters · filed 2021-02-03 |
| 2018-12-31 | $38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $88.40M derived: sum of 2 quarters · filed 2021-02-03 | $131.20M derived: sum of 3 quarters · filed 2021-02-03 | $181.60M 10-K · filed 2021-02-03 |
| 2018-09-30 | $50.40M 10-Q · filed 2019-10-22 | $93.20M derived: sum of 2 quarters · filed 2019-10-22 | $143.60M 10-Q · filed 2019-10-22 | $185.70M derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-06-30 | $42.80M 10-Q · filed 2019-07-24 | $93.20M 10-Q · filed 2019-07-24 | $135.30M derived: sum of 3 quarters · filed 2020-02-06 | $178.40M derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-03-31 | $50.40M 10-Q · filed 2019-04-24 | $92.50M derived: sum of 2 quarters · filed 2020-02-06 | $135.60M derived: sum of 3 quarters · filed 2020-02-06 | $172.00M derived: sum of 4 quarters · filed 2020-02-06 |
| 2017-12-31 | $42.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $85.20M derived: sum of 2 quarters · filed 2020-02-06 | $121.60M derived: sum of 3 quarters · filed 2020-02-06 | $169.70M 10-K · filed 2020-02-06 |
| 2017-09-30 | $43.10M 10-Q · filed 2018-10-23 | $79.50M derived: sum of 2 quarters · filed 2018-10-23 | $127.60M 10-Q · filed 2018-10-23 | $173.60M derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-06-30 | $36.40M 10-Q · filed 2018-07-24 | $84.50M 10-Q · filed 2018-07-24 | $130.50M derived: sum of 3 quarters · filed 2019-02-06 | $184.40M derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-03-31 | $48.10M 10-Q · filed 2018-04-24 | $94.10M derived: sum of 2 quarters · filed 2019-02-06 | $148.00M derived: sum of 3 quarters · filed 2019-02-06 | $198.20M derived: sum of 4 quarters · filed 2019-02-06 |
| 2016-12-31 | $46.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $99.90M derived: sum of 2 quarters · filed 2019-02-06 | $150.10M derived: sum of 3 quarters · filed 2019-02-06 | $204.40M 10-K · filed 2019-02-06 |
| 2016-09-30 | $53.90M 10-Q · filed 2017-10-24 | $104.10M derived: sum of 2 quarters · filed 2017-10-24 | $158.40M 10-Q · filed 2017-10-24 | $198.10M derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-06-30 | $50.20M 10-Q · filed 2017-07-25 | $104.50M 10-Q · filed 2017-07-25 | $144.20M derived: sum of 3 quarters · filed 2018-02-01 | $172.50M derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-03-31 | $54.30M 10-Q · filed 2017-04-25 | $94.00M derived: sum of 2 quarters · filed 2018-02-01 | $122.30M derived: sum of 3 quarters · filed 2018-02-01 | $170.60M derived: sum of 4 quarters · filed 2018-02-01 |
| 2015-12-31 | $39.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $68.00M derived: sum of 2 quarters · filed 2018-02-01 | $116.30M derived: sum of 3 quarters · filed 2018-02-01 | $207.30M 10-K · filed 2018-02-01 |
| 2015-09-30 | $28.30M 10-Q · filed 2016-10-26 | $76.60M derived: sum of 2 quarters · filed 2016-10-26 | $167.60M 10-Q · filed 2016-10-26 | $226.40M derived: sum of 4 quarters · filed 2017-02-02 |
| 2015-06-30 | $48.30M 10-Q · filed 2016-07-21 | $139.30M 10-Q · filed 2016-07-21 | $198.10M derived: sum of 3 quarters · filed 2017-02-02 | $257.00M derived: sum of 4 quarters · filed 2017-02-02 |
| 2015-03-31 | $91.00M 10-Q · filed 2016-04-21 | $149.80M derived: sum of 2 quarters · filed 2017-02-02 | $208.70M derived: sum of 3 quarters · filed 2017-02-02 | $266.80M derived: sum of 4 quarters · filed 2017-02-02 |
| 2014-12-31 | $58.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $117.70M derived: sum of 2 quarters · filed 2017-02-02 | $175.80M derived: sum of 3 quarters · filed 2017-02-02 | $252.40M 10-K · filed 2017-02-02 |
| 2014-09-30 | $58.90M 10-Q · filed 2015-10-21 | $117.00M derived: sum of 2 quarters · filed 2015-10-21 | $193.60M 10-Q · filed 2015-10-21 | $260.40M derived: sum of 4 quarters · filed 2016-02-03 |
| 2014-06-30 | $58.10M 10-Q · filed 2015-07-24 | $134.70M 10-Q · filed 2015-07-24 | $201.50M derived: sum of 3 quarters · filed 2016-02-03 | $262.10M derived: sum of 4 quarters · filed 2016-02-03 |
| 2014-03-31 | $76.60M 10-Q · filed 2015-04-24 | $143.40M derived: sum of 2 quarters · filed 2016-02-03 | $204.00M derived: sum of 3 quarters · filed 2016-02-03 | $273.10M derived: sum of 4 quarters · filed 2016-02-03 |
| 2013-12-31 | $66.80M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $127.40M derived: sum of 2 quarters · filed 2016-02-03 | $196.50M derived: sum of 3 quarters · filed 2016-02-03 | $255.90M 10-K · filed 2016-02-03 |
| 2013-09-30 | $60.60M 10-Q · filed 2014-10-22 | $129.70M derived: sum of 2 quarters · filed 2014-10-22 | $189.10M 10-Q · filed 2014-10-22 | |
| 2013-06-30 | $69.10M 10-Q · filed 2014-07-23 | $128.60M 10-Q · filed 2014-07-23 | ||
| 2012-12-31 | $184.30M 10-K · filed 2015-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |